Drug Abuse and Misuse

• Identify the dangers associated with the nonmedical use of prescription and OTC medications.
• Devise ways to prevent medication abuse in your patients and drug diversion/mis-use within your practice.
• Compare and contrast challenges with Prescription Drug Monitoring Programs and behind the counter status.
• Discuss the use of marijuana (and its active ingredients) for various medicinal purposes.

Understanding Patient’s Approaches in Self-Care

• Outline strategies for assessing and counseling patients on the use of OTC products in self-care.
• Describe patient’s attitudes about monitoring devices and diagnostics for self-care.
• Identify new personal health care technologies and the impact they may have on patient outcomes.

Optimizing Medication Adherence and Outcomes

• Create strategies to promote medications adherence among all healthcare providers.
• Describe the impact of poor adherence on clinical and economic outcomes for patient and stakeholders.
• Associate the necessary points within the medication use system in which technology can be employed to reduce medical errors and enhance patient outcomes.

From Pharmacogenomics to Personalized Medicine

• Distinguish the benefits and limitations of genetic testing and use in managing medications in specific patients.
• Identify new personal health care technologies and the impact they may have on patient outcomes.
• Evaluate various gene-drug (biomarker-drug) pairs with pharmacogenomic applications.

Comprehensive Medication Management Services

• Recognize the importance of aligning incentives in a "pay for performance" model that includes all providers.
• Outline the benefits of leveraging the prescription benefit to reduce downstream healthcare costs and outcomes.
• Critique the rationale for collaborative models of care that deliver enhanced clinical, patient and economic outcomes.

Pharmaceutical Regulatory Update, Key Product Approvals, Guideline Updates

• Describe the challenges associated with biosimilars and biologics and their interchangeability.
• Critique the FDA's role in pharmaceutical approvals, post-marketing safety surveillance and balancing the impact on consumer demand.
• Compare and contrast key recent drug approvals with those already used for specific conditions.
• Discuss pertinent pharmacotherapy changes to clinical guidelines.